Background: Sentinel lymph node biopsy (SLNB) is rapidly gaining acceptance as a diagnostic tool for staging breast cancer.
Introduction
The most precise prognostic indicator for progression of primary breast cancer is lymph node involvement. 1 For this reason, as well as for local disease control, most surgeons include some form of lymph node dissection in their initial case management of breast cancer. Sentinel lymph node biopsy (SLNB) has gained acceptance as a first line diagnostic approach because it is more sensitive and causes less morbidity than traditional techniques for early staging of breast cancer.
After SLNB was found successful for staging melanoma, Giuliano axillary node dissection. [3] [4] [5] [6] [7] Working at the Kaiser Permanente (KP) Los Angeles Medical Center, Guenther et al 8, 9 documented efficacy and safety of SLNB. By 1999, the National Comprehensive Cancer Network (NCCN) recognized the procedure had rapidly gained acceptance as an appropriate diagnostic tool for determining whether cancer has spread to the surrounding lymph nodes. The current NCCN Breast Cancer Practice Guidelines 10 support SLNB by experienced teams of practitioners for patients who meet selection criteria.
Beginning in 1994, the KP Oakland Medical Center (KP Oakland) used SLNB to stage cases of melanoma. On the basis of this experience, SLNB was introduced in 1996 to stage breast cancer. Early results confirmed that the method was reliable, and patients were pleased with the mild degree of post-surgical morbidity and short hospital stay.
I N N O V A T I O N

Sentinel lymph
node biopsy (SLNB) has gained acceptance as a first line diagnostic approach …
clinical contributions
Surgeons from other facilities joined KP Oakland in a collaborative trial that enrolled patients nationally. The KP Institutional Review Board approved the study. The trial provided an organized framework for accomplishing three goals: 1) to standardize use of SLNB in breast cancer staging, 2) to facilitate training of surgery and pathology teams, and 3) to establish a comprehensive database. 11 More than 40 centers from university and community hospital settings participated in this collaborative effort (titled The Early Detection of Occult Micrometastases in Invasive Breast Cancer), a prospective, multicenter trial which originated at the University of South Florida and was funded by both the US Department of Defense and the National Cancer Institute. KP patients were recruited from November 1997 through October 1999, and data from these patients constituted part of the database content. Initial results indicated that surgeons from participating facilities learned and reliably performed SLNB. Some long-term goals of the study are still in process and include determining the prognostic significance of micrometastases and evaluating use of polymerase chain reaction (PCR) as a diagnostic tool.
At The Breast Cancer Tracking System of KP Northern California (KPNC) contains data on all SLNB procedures done at KPNC since July 7, 1997 for breast cancer patients. Using these data, we studied trends among TPMG surgeons and at KPNC facilities in adopting techniques of sentinel lymph node identification, dissection, and biopsy, processes that require coordination among departments of surgery, pathology, radiology, and nuclear medicine. By mid-2003, more than 2100 cases had been recorded. Although the database does not indicate rate of successfully locating sentinel lymph nodes, the database does contain false-negative results, ie, positive results of axillary node biopsy in patients with negative results of sentinel lymph node biopsy. We used this false-negative rate for limited assessment of the success of SLNB among KP surgeons. The present study was done to assess quantitatively the rate of successful SLNB in patients with breast cancer and to identify possible ways to improve the rate. 14 The sentinel lymph node identification procedure combined preoperative Tc99m sulfur colloid peritumoral injection followed by lymphoscintigraphy and intraoperative isosulfan blue dye injection into the peritumoral region of the breast. Sentinel lymph nodes that were thus identified (ie, either as radioactive or blue) were removed for excisional biopsy. If no sentinel node was identified, standard level I (with or without level II) lymph node dissection and biopsy were done.
A false-negative result was defined as concurrent negative result of SLNB and positive result of axillary node biopsy. False-negative rate for the SLNB procedure (proportion of false-negative results to the sum of true positive and false-negative results) was calculated, both overall and stratified by surgeon experience with the procedure. Patients who had SLNB and biopsy without axillary node dissection were excluded from analyses of false-negative rate.
In almost all cases, serial sections of the node were permanently mounted, stained with hematoxylin-eosin, and microscopically examined to determine status of the sentinel lymph node. Initial pathologic examination was performed on-site at the surgical facility. At the KP San Francisco Medical Center, tissue was examined immunohistochemically for micrometastases, estrogen and progesterone receptors, and for over-expression of the HER-2/Neu gene.
Results
Between July 1997 and December 2002, 2098 patients with clinically negative lymph nodes had SLNB procedures. Of these 2098 patients, 437 patients did not have axillary node dissection and were excluded from the analysis of false-negative rates, and 1660 patients had standard level I or level II lymph node dissection with lumpectomy or modified radical mastectomy. The median age of patients was 59 years (range 23-95 years).
The monthly number of SLNB procedures increased steadily. Although fewer than ten per month were done in the first and second quarters of 1998, more than 30 procedures per month were done during the first quar- S a n F r a n c i s c o , C A S a n R a f a e l , C A S a n t a C l a r a , C A S a n t a R o s a , C A S a n t a T e r e s a , C A S o u t h S a n The overall false-negative rate was 6.53% (95% confidence interval [CI] 4.75%, 8.73%). The false-negative rate for surgeons who performed fewer than 30 procedures was 8.58% (95% CI 5.52%, 12.60%); the rate for surgeons who performed between 20 and 30 procedures was 13.08% (95% CI 7.34%, 20.98%); and the rate for surgeons who performed more than 30 procedures was 5.05% (95% CI 3.07%, 7.78%) (Figure 4 ).
Discussion
Surgical management of breast cancer has evolved in stages. Use of Halsted radical mastectomy was replaced first by modified radical mastectomy and later by conservative breast surgery. Treatment of axillary lymph nodes in patients with invasive breast cancer has always been controversial. Because as many as 70% of patients who undergo lymph node dissection have negative biopsy results 15 and because node dissection is often accompanied by postsurgical complications and morbidity, less-invasive methods were developed for staging breast cancer. This development was facilitated in particular by use of mammography and by earlier diagnosis of breast cancer (ie, when the tumor is small). Because the axillary lymph nodes of most breast cancer patients seen today are clinically and pathologically negative, the need for less invasive breast cancer staging is being met by SLNB.
The KPNC Breast Cancer Tracking System shows that SLNB is now performed regularly by Northern California TPMG surgeons. Introduction of new surgical procedures usually follows a pattern: Selected surgeons become familiar with the technique and then proctor other surgeons until the procedure becomes widely practiced. This pattern was suggested by our data. Of the 132 surgeons in the study, 58 performed SLNB fewer than five times during the period analyzed, and most (56%) of the 2098 procedures were performed by only 20 (15%) of the surgeons. This pattern also reflects a current trend in surgical practice: surgical subspecialization (ie, more breast cancer management is being done by fewer surgeons).
The ability to perform SLNB is measured primarily by the surgeon's rate of success in finding the sentinel lymph node and by the corresponding false-negative rate. Because this study was retrospective, the rate of successfully finding the sentinel lymph node could not be tracked. Combined use of blue dye and radioisotope allows surgeons to find the sentinel lymph node in 81% to 94% of patients. 16 In a prospective study conducted throughout 1998 and 1999, TPMG surgeons had a 97% rate of successfully locating the sentinel lymph node. Although no data verify similar success for the surgeons in our study, early prospective study data are reassuring. Further, surgeons who could not locate a sentinel lymph node proceeded with standard lymph node dissection.
The rate of false-negative results best defines the accuracy of sentinel lymph node biopsy. If a sentinel node which tests negative for tumor cells at histologic examination is removed while a tumor-positive lymph node remains in the axilla, the disease will be understaged, leaving the patient at risk both for local and regional recurrence of disease and for metastasis. Sentinel
I N N O V A T I O N clinical contributions
A false-negative rate of 5% or less is mentioned frequently in surgical literature as a goal for surgeons performing SLNB. 17, 18 All TPMG surgeons combined had a 6.5% false-negative rate for the SLNB procedure. Because this rate was calculated for a large number of surgeons gaining early experience with the SLNB technique, the 6.5% rate affirms that promising introduction of a technology and technique.
How many times must surgeons perform SLNB before they achieve proficiency in this procedure? The 6.5% false-negative rate for all KP surgeons compares favorably with the goal of a 5% or less rate of falsenegative results advocated in the general literature. 17, 18 However, our data show some conflicting trends: Whereas surgeons who performed fewer than 30 or more than 30 SLNB procedures had low false-negative rates (8.6% and 5%, respectively), surgeons who performed an intermediate number of SLNB procedures (20 to 30 procedures) had a higher rate of false-negative results (13%). Although the rates of false-negative results in national SLNB trials range from 0% to 17% 17 and surgeons less experienced in the technique have higher false-negative rate, 18 surgeons in our series who had an intermediate level of experience (20 to 30 SLNB procedures completed) had the highest rate of falsenegative results. This unexpectedly high rate may reflect inadequate proctoring, lack of surgical proficiency, or inappropriate selection of patients (ie, selecting patients who have advanced disease). The better false-negative rate among surgeons who performed fewer than 20 procedures may represent the combined experience of apprentice surgeons and their proctors; the false-negative rate may then have increased among the apprentice surgeons after they began to perform the SLNB procedure unassisted (especially after only a few proctored SLNB procedures) until more experience was gained. Data analysis (not presented here) confirmed that the entire group of KP surgeons and the group with an intermediate level of experience performed SLNB for similar percentages of patients with advanced disease. Data were not available describing surgical proficiency, selection of patients with advanced disease, or availability of a proctor during the SLNB procedure.
The proposed number of times a surgeon must perform the SLNB procedure before achieving proficiency in it ranges from 10 to 150. [19] [20] [21] However, many authors suggest that experience with 20 to 30 SLNB procedures may be adequate, 17 if the surgeon has received good proctoring and case management is coordinated jointly by a team of surgeons, radiologists, nuclear medicine specialists, and pathologists. Our data 10 In addition, our data justify adopting a departmental policy which specifies the minimum surgical caseloads and monitors surgical results to verify a low rate of false-negative results (5% or less) for surgeons who have performed SLNB 20 or more times.
Continuing to Provide High-Quality Service
TPMG surgeons should be encouraged to monitor patients prospectively and to support development of a national database. To advance toward these goals, TPMG surgeons should participate in sentinel node biopsy trials such as the National Surgical Adjuvant Breast and Bowel Project study (NSABP) B32 22 or the American College of Surgeons Oncology Group trials (ACSOG) Z-10 or Z-11. 23 The NSABP B32 trial compares patients undergoing full axillary dissection and patients receiving SLNB only. However, all patients with positive sentinel lymph nodes will have complete axillary node dissection. In contrast, the ACSOG trials will include patients with positive sentinel lymph nodes who do not undergo further surgery. The Z-10 trial will further assess the benefit of bone marrow biopsy for determining presence of metastatic disease.
Dr Lou Fehrenbacher of KP Vallejo has provided infrastructure for NSABP and other trials regionally, and TPMG surgeons have already contributed to the first national prospective SLNB trial. 11 In addition, using the Breast Cancer Tracking System, we have monitored 2098 cases and have established an independent database which facilitates prospective and retrospective quality review. As these data are transferred from a local database to the Population and Condition Tracking System (PACTS)-a Web-based application designed to track multiple conditions, including many types of cancerclinical outcome must remain the focus in all surgical cases. This focus of all our departments will help ensure that KP surgeons remain at the forefront of advances in therapy and that we offer our patients the best possible treatment for breast cancer and other conditions. ❖
